Analyst Price Target is $285.68
▲ +12.07% Upside Potential
This price target is based on 24 analysts offering 12 month price targets for Humana in the last 3 months. The average price target is $285.68, with a high forecast of $385.00 and a low forecast of $250.00. The average price target represents a 12.07% upside from the last price of $254.92.
Current Consensus is
Hold
The current consensus among 24 polled investment analysts is to hold stock in Humana. This rating has held steady since March 2024, when it changed from a Moderate Buy consensus rating.
Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of pharmacy benefit manager business. Further, it operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. The company sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
Read More